Content area

|
|

Adjuverende medicinsk behandling tilpatienter med lokoregionalt recidiv af brystkræft

Isoleret lokoregionalt recidiv af brystkræft.
Forfatter(e)
Farah Choudary Farooq1 & Claus Kamby2 1) Onkologisk Afdeling, Roskilde Sygehus 2) Onkologisk Klinik, Rigshospitalet Ugeskr Læger 2016;178:V08150648
Reference: 
Ugeskr Læger 2016;178:V08150648
Blad nummer: 
Sidetal: 
2-5
Adjuvant medical treatment for patients with locoregional recurrence of breast cancer
There is 10-30% risk of developing isolated locoregional recurrence (ILRR) after mastectomy for primary breast cancer. Currently, there is no standard treatment for ILRR and therefore patients with ILRR cause an oncological task. This review investigates existing literature concerning relevant randomized trials of adjuvant medical treatment with chemotherapy, anti-hormonal and anti HER2 treatments for patients radically treated for ILRR. Certain groups of patients may benefit from adjuvant systemic treatment. However larger randomized trials are needed.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anne Gersdorff Korsgaard | 20/10
1 Kommentar
af Karen Brink Linnet | 19/10
1 Kommentar
af Thor Andersen Knudsen | 19/10
2 kommentarer
af Ole Lindgård Dollerup | 18/10
1 Kommentar
af Kristine Rasmussen | 18/10
1 Kommentar
af Camilla Bang | 16/10
1 Kommentar
af Tobias Ramm Eberlein | 15/10
6 kommentarer
af Frank Bang Nissen | 15/10
1 Kommentar